Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Puschmann Andreas) "

Sökning: WFRF:(Puschmann Andreas)

  • Resultat 31-40 av 90
  • Föregående 123[4]567...9Nästa
Sortera/gruppera träfflistan
  • LeDoux, MS, et al. (författare)
  • Genotype–phenotype correlations in THAP1 dystonia: Molecular foundations and description of new cases
  • 2012
  • Ingår i: Parkinsonism & Related Disorders. - : Elsevier. - 1873-5126 .- 1353-8020. ; 18:5, s. 414-425
  • Tidskriftsartikel (refereegranskat)abstract
    • An extensive variety of THAP1 sequence variants have been associated with focal, segmental and generalized dystonia with age of onset ranging from 3 to over 60 years. In previous work, we screened 1114 subjects with mainly adult-onset primary dystonia (Neurology 2010; 74:229-238) and identified 6 missense mutations in THAP1. For this report, we screened 750 additional subjects for mutations in coding regions of THAP1 and interrogated all published descriptions of THAP1 phenotypes (gender, age of onset, anatomical distribution of dystonia, family history and site of onset) to explore the possibility of THAP1 genotype-phenotype correlations and facilitate a deeper understanding of THAP1 pathobiology. We identified 5 additional missense mutations in THAP1 (p.A7D, p.K16E, p.S21C, p.R29Q, and p.I80V). Three of these variants are associated with appendicular tremors, which were an isolated or presenting sign in some of the affected subjects. Abductor laryngeal dystonia and mild blepharospasm can be manifestations of THAP1 mutations in some individuals. Overall, mean age of onset for THAP1 dystonia is 16.8 years and the most common sites of onset are the arm and neck, and the most frequently affected anatomical site is the neck. In addition, over half of patients exhibit either cranial or laryngeal involvement. Protein truncating mutations and missense mutations within the THAP domain of THAP1 tend to manifest at an earlier age and exhibit more extensive anatomical distributions than mutations localized to other regions of THAP1.
  • Lindquist, SG, et al. (författare)
  • Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease
  • 2013
  • Ingår i: Clinical Genetics. - : Wiley-Blackwell. - 0009-9163. ; 83:3, s. 279-283
  • Tidskriftsartikel (refereegranskat)abstract
    • Recently, a hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72 was reported as the cause of chromosome 9p21-linked frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS). We here report the prevalence of the expansion in a hospital-based cohort and associated clinical features indicating a wider clinical spectrum of C9ORF72 disease than previously described. We studied 280 patients previously screened for mutations in genes involved in early onset autosomal dominant inherited dementia disorders. A repeat-primed polymerase chain reaction amplification assay was used to identify pathogenic GGGGCC expansions. As a potential modifier, confirmed cases were further investigated for abnormal CAG expansions in ATXN2. A pathogenic GGGGCC expansion was identified in a total of 14 probands. Three of these presented with atypical clinical features and were previously diagnosed with clinical olivopontocerebellar degeneration (OPCD), atypical Parkinsonian syndrome (APS) and a corticobasal syndrome (CBS). Further, the pathogenic expansion was identified in six FTD patients, four patients with FTD-ALS and one ALS patient. All confirmed cases had normal ATXN2 repeat sizes. Our study widens the clinical spectrum of C9ORF72related disease and confirms the hexanucleotide expansion as a prevalent cause of FTD-ALS disorders. There was no indication of a modifying effect of the ATXN2 gene.
  • Liu, Hui, et al. (författare)
  • Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors
  • 2022
  • Ingår i: Annals of Neurology. - : John Wiley & Sons Inc.. - 1531-8249. ; 92:2, s. 270-278
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: The aim of the current study is to understand why some individuals avoid developing Parkinson disease (PD) despite being at relatively high genetic risk, using the largest datasets of individual-level genetic data available.METHODS: We calculated polygenic risk score to identify controls and matched PD cases with the highest burden of genetic risk for PD in the discovery cohort (International Parkinson's Disease Genomics Consortium, 7,204 PD cases and 9,412 controls) and validation cohorts (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease, 8,968 cases and 7,598 controls; UK Biobank, 2,639 PD cases and 14,301 controls; Accelerating Medicines Partnership-Parkinson's Disease Initiative, 2,248 cases and 2,817 controls). A genome-wide association study meta-analysis was performed on these individuals to understand genetic variation associated with resistance to disease. We further constructed a polygenic resilience score, and performed multimarker analysis of genomic annotation (MAGMA) gene-based analyses and functional enrichment analyses.RESULTS: A higher polygenic resilience score was associated with a lower risk for PD (β = -0.054, standard error [SE] = 0.022, p = 0.013). Although no single locus reached genome-wide significance, MAGMA gene-based analyses nominated TBCA as a putative gene. Furthermore, we estimated the narrow-sense heritability associated with resilience to PD (h2 = 0.081, SE = 0.035, p = 0.0003). Subsequent functional enrichment analysis highlighted histone methylation as a potential pathway harboring resilience alleles that could mitigate the effects of PD risk loci.INTERPRETATION: The present study represents a novel and comprehensive assessment of heritable genetic variation contributing to PD resistance. We show that a genetic resilience score can modify the penetrance of PD genetic risk factors and therefore protect individuals carrying a high-risk genetic burden from developing PD. ANN NEUROL 2022;92:270-278.
  • Patterson, Marc C., et al. (författare)
  • Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C : an observational cohort study
  • 2015
  • Ingår i: Orphanet Journal of Rare Diseases. - : BioMed Central (BMC). - 1750-1172. ; 10, s. 65-65
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Niemann-Pick disease type C (NP-C) is a rare neurovisceral disease characterised by progressive neurological degeneration, where the rate of neurological disease progression varies depending on age at neurological onset. We report longitudinal data on functional disease progression and safety observations in patients in the international NPC Registry who received continuous treatment with miglustat.METHODS: The NPC Registry is a prospective observational cohort of NP-C patients. Enrolled patients who received ≥1 year of continuous miglustat therapy (for ≥90 % of the observation period, with no single treatment interruption >28 days) were included in this analysis. Disability was measured using a scale rating the four domains, ambulation, manipulation, language and swallowing from 0 (normal) to 1 (worst). Neurological disease progression was analysed in all patients based on: 1) annual progression rates between enrolment and last follow up, and; 2) categorical analysis with patients categorised as 'improved/stable' if ≥3/4 domain scores were lower/unchanged, and as 'progressed' if <3 scores were lower/unchanged between enrolment and last follow-up visit.RESULTS: In total, 283 patients were enrolled from 28 centers in 13 European countries, Canada and Australia between September 2009 and October 2013; 92 patients received continuous miglustat therapy. The mean (SD) miglustat exposure during the observation period (enrolment to last follow-up) was 2.0 (0.7) years. Among 84 evaluable patients, 9 (11 %) had early-infantile (<2 years), 27 (32 %) had late-infantile (2 to <6 years), 30 (36 %) had juvenile (6 to <15 years) and 18 (21 %) had adolescent/adult (≥15 years) onset of neurological manifestations. The mean (95%CI) composite disability score among all patients was 0.37 (0.32,0.42) at enrolment and 0.44 (0.38,0.50) at last follow-up visit, and the mean annual progression rate was 0.038 (0.018,0.059). Progression of composite disability scores appeared highest among patients with neurological onset during infancy or childhood and lowest in those with adolescent/adult-onset. Overall, 59/86 evaluable patients (69 %) were categorized as improved/stable and the proportion of improved/stable patients increased with age at neurological onset. Safety findings were consistent with previous data.CONCLUSIONS: Disability status was improved/stable in the majority of patients who received continuous miglustat therapy for an average period of 2 years.
  • Perez-Soriano, Alexandra, et al. (författare)
  • PBB3 imaging in Parkinsonian disorders : Evidence for binding to tau and other proteins
  • 2017
  • Ingår i: Movement Disorders. - : John Wiley & Sons Inc.. - 0885-3185. ; 32:7, s. 1016-1024
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND AND OBJECTIVES: To study selective regional binding for tau pathology in vivo, using PET with [(11) C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy.METHODS: Dynamic PET scans were obtained for 70 minutes after the bolus injection of [(11) C]PBB3 in 5 PSP subjects, 1 subject with DCTN1 mutation and PSP phenotype, 3 asymptomatic SNCA duplication carriers, 1 MSA subject, and 6 healthy controls of similar age. Tissue reference Logan analysis was applied to each region of interest using a cerebellar white matter reference region.RESULTS: In comparison to the control group, PSP subjects showed specific uptake of [(11) C]PBB3 in putamen, midbrain, GP, and SN. Longer disease duration and more advanced clinical severity were generally associated with higher tracer retention. A DCTN1/PSP phenotype case showed increased binding in putamen, parietal lobe, and GP. In SNCA duplication carriers, there was a significant increase of [(11) C] PBB3 binding in GP, putamen, thalamus, ventral striatum, SN, and pedunculopontine nucleus. The MSA case showed increased binding in frontal lobe, GP, midbrain, parietal lobe, putamen, temporal lobe, SN, thalamus, and ventral striatum.CONCLUSIONS: All PSP patients showed increased retention of the tracer in the basal ganglia, as expected. Binding was also present in asymptomatic SNCA duplication carriers and in an MSA case, which are not typically associated with pathological tau deposition. This suggests the possibility that [(11) C]PBB3 binds to alpha-synuclein. © 2017 International Parkinson and Movement Disorder Society.
  • Prudencio, Mercedes, et al. (författare)
  • Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3
  • 2020
  • Ingår i: Science Translational Medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6242 .- 1946-6234. ; 12:566
  • Tidskriftsartikel (refereegranskat)abstract
    • Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates. Although there is no cure for SCA3, gene-silencing approaches to reduce toxic polyQ ATXN3 showed promise in preclinical models. However, a major limitation in translating putative treatments for this rare disease to the clinic is the lack of pharmacodynamic markers for use in clinical trials. Here, we developed an immunoassay that readily detects polyQ ATXN3 proteins in human biological fluids and discriminates patients with SCA3 from healthy controls and individuals with other ataxias. We show that polyQ ATXN3 serves as a marker of target engagement in human fibroblasts, which may bode well for its use in clinical trials. Last, we identified a single-nucleotide polymorphism that strongly associates with the expanded allele, thus providing an exciting drug target to abrogate detrimental events initiated by mutant ATXN3. Gene-silencing strategies for several repeat diseases are well under way, and our results are expected to improve clinical trial preparedness for SCA3 therapies.
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 90
  • Föregående 123[4]567...9Nästa
Typ av publikation
tidskriftsartikel (72)
konferensbidrag (11)
forskningsöversikt (3)
bokkapitel (3)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (83)
övrigt vetenskapligt (5)
populärvet., debatt m.m. (2)
Puschmann, Andreas (89)
Wszolek, Zbigniew K. (31)
Ross, Owen A. (19)
Nilsson, Christer (12)
Opala, Grzegorz (11)
Uitti, Ryan J (10)
visa fler...
Lynch, Timothy (10)
Hansson, Oskar (8)
Englund, Elisabet (8)
Widner, Håkan (8)
Silburn, Peter A. (8)
Mellick, George D. (8)
Wirdefeldt, Karin (8)
Aasly, Jan O. (8)
Annesi, Grazia (8)
Jasinska-Myga, Barba ... (8)
Maraganore, Demetriu ... (8)
Ilinca, Andreea (7)
Dickson, Dennis W (7)
Brighina, Laura (7)
Brice, Alexis (7)
Soto-Ortolaza, Alexa ... (7)
Sharma, Manu (7)
Van Broeckhoven, Chr ... (6)
Lesage, Suzanne (6)
Elbaz, Alexis (6)
Hadjigeorgiou, Georg ... (6)
Quattrone, Aldo (6)
Nilsson, Karin (5)
Swanberg, Maria (5)
Soller, Maria (5)
Hattori, Nobutaka (5)
Theuns, Jessie (5)
Klein, Christine (5)
Wszolek, Z K (5)
Aasly, Jan (5)
Bozi, Maria (5)
Ferrarese, Carlo (5)
van Westen, Danielle (4)
Kruger, R (4)
Fiesel, Fabienne C. (4)
Springer, Wolfdieter (4)
Chartier-Harlin, Mar ... (4)
Markopoulou, Katerin ... (4)
Tan, Eng-King (4)
Ygland Rödström, Emi ... (4)
Rudzinska, Monika (4)
Gibson, J. Mark (4)
Stefanis, Leonidas (4)
visa färre...
Lunds universitet (89)
Karolinska Institutet (11)
Göteborgs universitet (5)
Linköpings universitet (2)
Umeå universitet (1)
Uppsala universitet (1)
visa fler...
Örebro universitet (1)
visa färre...
Engelska (89)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (88)
Naturvetenskap (2)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy